Founder of Peptidings.com. Former big tech product manager. Independent peptide researcher focused on translating clinical evidence into accessible science.
Novo Nordisk’s next-generation weight-loss candidate CagriSema — a fixed-ratio combination of semaglutide and the amylin analog cagrilintide — failed to demonstrate superiority […]
MIT Technology Review published a feature on February 23 documenting what anyone in the peptide space already knew — and what
Novo Nordisk’s Wegovy pill — oral semaglutide at 25 mg, once daily — became commercially available in January 2026, following FDA approval in